Foretinib phosphate
Based on 17 publication(s) in Google Scholar
Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1226999-07-0
- Formule: C34H40F2N4O14P2
- Masse moléculaire:828.64
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Foretinib phosphate
More- Cancer Discov. 2021 Jan;11(1):126-141. [Abstract]
- Nat Biomed Eng. 2018 Aug;2(8):578-588. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- J Exp Clin Cancer Res. 2024 Nov 20;43(1):308. [Abstract]
- Cell Chem Biol. 2018 Feb 15;25(2):206-214.e11. [Abstract]
- Clin Transl Med. 2025 May;15(5):e70338. [Abstract]
- RSC Adv. 2019 Feb 7;9(9):4862-4869. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- J Cell Mol Med. 2026 Apr;30(7):e71101. [Abstract]
- BMC Cancer. 2026 May 4;26(1):768. [Abstract]
- Open Chem. 2020 Jun.
- Biomed Chromatogr. 2020 Aug;34(8):e4862. [Abstract]
- J Pancreatol. 2023 Dec 12.
- bioRxiv. 2026 May 22:2026.05.20.726507. [Abstract]
- bioRxiv. 2025 Jul 21:2025.07.16.665230. [Abstract]
- J Pers Med. 2022 Aug 1;12(8):1270. [Abstract]
- Technical University of Munich. 24.01.2018.
Voir tous les produits spécifiques à Isoform VEGFR
More
Activité biologique
|
VEGFR2 |
Chemical Information
-
CAS No. 1226999-07-0
-
Masse moléculaire 828.64
-
Formule C34H40F2N4O14P2
-
SMILES
O=C(C1(CC1)C(NC2=CC=C(C(F)=C2)OC3=C4C=C(OC)C(OCCCN5CCOCC5)=CC4=NC=C3)=O)NC6=CC=C(C=C6)F.O=P(O)(O)O.O=P(O)(O)O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
2021 Jan;11(1):126-141. PMID: 33004339 -
Nat Biomed Eng
TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. [Abstract]2018 Aug;2(8):578-588. PMID: 31015631 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
J Exp Clin Cancer Res
Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer. [Abstract]2024 Nov 20;43(1):308. PMID: 39567998 -
Cell Chem Biol
Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement. [Abstract]2018 Feb 15;25(2):206-214.e11. PMID: 29174542 -
Clin Transl Med
2025 May;15(5):e70338. PMID: 40437874 -
RSC Adv
A simple liquid chromatography-tandem mass spectrometry method to accurately determine the novel third-generation EGFR-TKI naquotinib with its applicability to metabolic stability assessment. [Abstract]2019 Feb 7;9(9):4862-4869. PMID: 35514667 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
J Cell Mol Med
2026 Apr;30(7):e71101. PMID: 41896195 -
BMC Cancer
PPP4C: a potential molecular marker and therapeutic target in thyroid cancer and triple-negative breast cancer. [Abstract]2026 May 4;26(1):768. PMID: 42082953 -
-
Biomed Chromatogr
LC-MS/MS assay for the quantification of foretinib in rat plasma and its application to preclinical pharmacokinetic study. [Abstract]2020 Aug;34(8):e4862. PMID: 32307722 -
-
bioRxiv
2026 May 22:2026.05.20.726507. PMID: 42239232 -
bioRxiv
2025 Jul 21:2025.07.16.665230. PMID: 40777316 -
J Pers Med
Wnt/β-Catenin-Pathway Alterations and Homologous Recombination Deficiency in Cholangiocarcinoma Cell Lines and Clinical Samples: Towards Specific Vulnerabilities. [Abstract]2022 Aug 1;12(8):1270. PMID: 36013219 -
Pureté et documentation
Références
[1]. Qian F, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res, 2009, 69(20), 8009-8016. [Content Brief]
[2]. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets [Content Brief]
[3]. Kataoka Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs, 2011. [Content Brief]
[4]. Eder JP, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res, 2010, 16(13), 3507-3516. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Foretinib phosphate Related Classifications
HY-10338A Related Classifications
Powered by Bioz